Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...

Both drugs are JAK 1/2 inhibitors and have been cleared for use in adults with severe hair loss caused by the condition. Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming ...

Mumbai: Sun Pharma's much anticipated US commercial launch of its specialty product Leqselvi (deuruxolitinib) is facing uncertainty due to a patent dispute. Leqselvi is used for the treatment of ...

Both drugs are already approved in the US ... sought by Incyte on the launch of Sun Pharma's recently approved Leqselvi for alopecia areata.

Sun Pharmaceutical Industries has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and ...

Leqselvi is now FDA approved for treating severe alopecia areata. Sun Pharma added the oral drug to its pipeline via the $576 million acquisition of Concert Pharmaceuticals last year. Sun ...

However, on Friday, the court upheld the delay, effectively blocking Leqselvi’s entry into the U.S. market. In response, Sun Pharma stated in an exchange filing on Saturday, “We respectfully ...

Of the states that do provide coverage for JAK inhibitors used to treat patients with alopecia, researchers found that prior ...

These include slower-than-expected sales pick-up for key specialty brands, further delays in the launch of Leqselvi ... inhibitor drugs, which compete with Sun’s Ilumya brand, reported strong ...